Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Stimmer, Lev ^a   Dehay, Sabrina ^a   Nemati, Fariba ^b   Massonnet, Gerald ^b   Richon, Sophie ^c   Decaudin, Didier ^b   Klijanienko, Jerzy ^b   Johannes, Ludger ^a  

^a CNRS UMR3666   (France)

^b INSTITUT CURIE   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Breast cancer; ESL; Gb3; Shiga toxin; STxB

Indexed keywords

B SUBUNIT OF SHIGA TOXIN; CYANINE DYE 3; ESTROGEN RECEPTOR; GLYCOSPHINGOLIPID; GLYCOSPHINGOLIPID GB3; SHIGA TOXIN; UNCLASSIFIED DRUG; GB3 ANTIGEN; STXB TOXIN; TUMOR ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER MORPHOLOGY; CONTROLLED STUDY; CYTOLOGY; DRUG TARGETING; EPITHELIUM CELL; EX VIVO STUDY; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TOXIN ANALYSIS; TUMOR CELL; ADENOFIBROMA; ANIMAL; BREAST; BREAST TUMOR; CARCINOMA; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MAMMARY GLAND; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADENOFIBROMA; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOPSY, FINE-NEEDLE; BREAST; BREAST NEOPLASMS; CARCINOMA; DRUG DELIVERY SYSTEMS; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MAMMARY GLANDS, HUMAN; MICE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; RECEPTORS, ESTROGEN; SHIGA TOXINS;

EID: 84924347393     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-916     Document Type: Article

References (38)

1. Johnston SR: The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur J Cancer 2011,47(Suppl 3):S38-S47.
2. Shamseddine AI, Farhat FS: Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011,57(6):468-487. 10.1159/000334093
3. Ivarsson ME, Leroux JC, Castagner B: Targeting bacterial toxins. Angew Chem Int Ed Engl 2012,51(17):4024-4045. doi:10.1002/anie.201104384. Epub 2012 Mar 22 10.1002/anie.201104384
4. Engedal N, Skotland T, Torgersen ML, Sandvig K: Shiga toxin and its use in targeted cancer therapy and imaging. Microb Biotechnol 2011,4(1):32-46. 10.1111/j.1751-7915.2010.00180.x
5. Johannes L, Romer W: Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol 2010,8(2):105-116.
6. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F: The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 2006,4(4):289-297. 10.2174/187152506778520718
7. Römer W, Berland L, Chambon V, Gaus K, Windschiegl B, Tenza D, Aly MR, Fraisier V, Florent JC, Perrais D, Lamaze C, Raposo G, Steinem C, Sens P, Bassereau P, Johannes L: Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007,450(7170):670-675. 10.1038/nature05996
8. Johannes L, Popoff V: Tracing the retrograde route in protein trafficking. Cell 2008,135(7):1175-1187. 10.1016/j.cell.2008.12.009
9. Hakomori S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996,56(23):5309-5318.
10. Johansson D, Kosovac E, Moharer J, Ljuslinder I, Brannstrom T, Johansson A, Behnam-Motlagh P: Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer 2009, 9:67. 10.1186/1471-2407-9-67
11. Wei F, Cao S, Ren X, Liu H, Yu J, Li H, Hao X: Efficient antiproliferative and antiangiogenic effects on human ovarian cancer growth by gene transfer of attenuated mutants of Shiga-like toxin I. Int J Gynecol Cancer 2008,18(4):677-691. 10.1111/j.1525-1438.2007.01090.x
12. Maak M, Nitsche U, Keller L, Wolf P, Sarr M, Thiebaud M, Rosenberg R, Langer R, Kleeff J, Friess H, Johannes L, Janssen KP: Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. Mol Cancer Ther 2011,10(10):1918-1928. 10.1158/1535-7163.MCT-11-0006
13. Distler U, Souady J, Hulsewig M, Drmic-Hofman I, Haier J, Friedrich AW, Karch H, Senninger N, Dreisewerd K, Berkenkamp S, Schmidt MA, Peter-Katalinić J, Müthing J: Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS One 2009,4(8):e6813. 10.1371/journal.pone.0006813
14. Falguieres T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther 2008,7(8):2498-2508. 10.1158/1535-7163.MCT-08-0430
15. Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR: The treatment of malignant meningioma with verotoxin. Neoplasia 2002,4(4):304-311. 10.1038/sj.neo.7900243
16. Arab S, Rutka J, Lingwood C: Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol Res 1999,11(1):33-39.
17. Heath-Engel HM, Lingwood CA: Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis 2003,6(2):129-141.
18. Ishitoya S, Kurazono H, Nishiyama H, Nakamura E, Kamoto T, Habuchi T, Terai A, Ogawa O, Yamamoto S: Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol 2004,171(3):1309-1313. 10.1097/01.ju.0000100110.11129.85
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011,22(8):1736-1747. 10.1093/annonc/mdr304
20. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E: Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012,14(1):R11. 10.1186/bcr3095
21. Mallard F, Johannes L: Shiga toxin B-subunit as a tool to study retrograde transport. Methods Mol Med 2003, 73:209-220.
22. Falguieres T, Mallard F, Baron C, Hanau D, Lingwood C, Goud B, Salamero J, Johannes L: Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol Biol Cell 2001,12(8):2453-2468. 10.1091/mbc.12.8.2453
23. Petit V, Massonnet G, Maciorowski Z, Touhami J, Thuleau A, Nemati F, Laval J, Chateau-Joubert S, Servely JL, Vallerand D, Fontaine JJ, Taylor N, Battini JL, Sitbon M, Decaudin D: Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters. Lab Invest 2013,93(5):611-621. doi:10.1038/labinvest.2013.44. Epub 2013 Mar 4 10.1038/labinvest.2013.44
24. Wilkinson AR, Mahore SD, Maimoon SA: FNAC in the diagnosis of lymph node malignancies: a simple and sensitive tool. Indian J Med Paediatr Oncol 2012,33(1):21-24. 10.4103/0971-5851.96964
25. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ: Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009,29(5):1557-1562.
26. de Plater L, Lauge A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E: Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 2012,103(8):1192-1200.
27. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF: A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007,13(13):3989-3998. 10.1158/1078-0432.CCR-07-0078
28. Devenica D, Cikes Culic V, Vuica A, Markotic A: Biochemical, pathological and oncological relevance of Gb3Cer receptor. Med Oncol 2011,28(Suppl 1):S675-S684.
29. Arab S, Russel E, Chapman WB, Rosen B, Lingwood CA: Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol Res 1997,9(10):553-563.
30. Pervez S, Shaikh H, Aijaz F, Aziz SA, Naqvi M, Hasan SH: Immunohistochemical estrogen receptor determination in human breast carcinoma: correlation with histologic differentiation and age of the patients. J Pak Med Assoc 1994,44(6):133-136.
31. Potapenko IO, Haakensen VD, Luders T, Helland A, Bukholm I, Sorlie T, Kristensen VN, Lingjaerde OC, Borresen-Dale AL: Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol 2010,4(2):98-118. 10.1016/j.molonc.2009.12.001
32. Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K, Hakomori SI: Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A 2013,110(13):4968-4973. 10.1073/pnas.1302825110
33. Vignot S, Besse B, Andre F, Spano JP, Soria JC: Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 2012,84(3):301-313. doi:10.1016/j.critrevonc.2012.05.002. Epub 2012 Jun 17 10.1016/j.critrevonc.2012.05.002
34. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012,30(6):593-599. 10.1200/JCO.2010.33.8889
35. Muthing J, Distler U: Advances on the compositional analysis of glycosphingolipids combining thin-layer chromatography with mass spectrometry. Mass Spectrom Rev 2010,29(3):425-479.
36. Johansson D, Andersson C, Moharer J, Johansson A, Behnam-Motlagh P: Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells. Br J Cancer 2010,102(2):383-391. 10.1038/sj.bjc.6605467
37. Lin C, Chen DR, Chang KJ, Chang TW, Wang HC: A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers. Cancer Chemother Pharmacol 2012,69(5):1363-1368. doi:10.1007/s00280-012-1841-y. Epub 2012 Feb 19 10.1007/s00280-012-1841-y
38. Kasibhatla S, Tseng B: Why target apoptosis in cancer treatment? Mol Cancer Ther 2003,2(6):573-580.